Participation in projects 2013-2018
Project MIP-14192/2014 "Long term consequences of gestational diabetes and obesity on health of mothers and their offspring". Project manager: Dr. Jilda Veličkienė. The duration of the project was from 01.05.2014 to 31.12.2016. Project budget was 71912,65 euros. Source of funding: Lithuanian Science Council.
Aim: To evaluate long term consequences of gestational diabetes on health of mothers and their offspring.
1. To assess the prevalence of obesity in women of reproductive age 15-20 years period.
2. Long term consequences evaluation (>15years) of gestational diabetes/obesity for mothers and their children's health (carbohydrate, lipid metabolism, body composition, mental health, eating habits, physical activity, social status, diabetes and cardiovascular the risk of disease).
3. To compare the results of sibling, who were born in the pathological pregnancy complicated gestational diabetes and / or obesity and normal pregnancy, health condition.
4. To assess the frequency of complications of diabetes in subjects with impaired glucose tolerance or diabetes.
5. To evaluate type 2 diabetes mellitus mostly predisposing gene TCF7L2 single nucleotide polymorphisms (rs7901695, rs7903146, rs7895340, rs11196205, rs12255372) with history of gestational diabetes in women and their children.
6. To prepare examination, monitoring and treatment recommendations for women who have been diagnosed with gestational diabetes.
7. To prepare examination and monitoring recommendations offspring whose mothers had gestational diabetes identified.
Project MIP-15445 „Cardiometabolic risk factors in Turner syndrome: prospective one population cohort study”. Project manager Prof. PhD Rasa Verkauskiene. Project start 01-04-2015, end of 2018-03-30. Budget - 87666 euros. Source of funding: Lithuanian Science Council.
The aim of the study: To identify the cardiometabolic risk factors in Turner syndrome (TS) population in Lithuania.
1. To investigate the prevalence of aortic lesions by using radiological evaluation methods (cardioechoscopy, magnetic resonance imaging) in TS population.
2. To identify the association between congenital cardiovascular abnormalities and aortic dilation in the assessed group.
3. To evaluate the influence of metabolic disorders and hormonal imbalance to aortic dilation in TS.
4. To compare the prevalence of Fibrilin-1 gene (FBL-1) single nucleotide polymorphisms (SNP) rs10519177 and rs211818 between TS and healthy females.
5. To identify the correlation between FBL-1 SNP’s rs10519177 and rs211818 and aortic diameter in TS.
6. To evaluate the correlation between cardiometabolic disorders, hormone imbalance and genetic features and aortic diameter changes in TS during 18 months.
7. To assess the psychoemotional state, congenital functions, sexual function and quality of life in TS population.
Project SEN-14/2015 "Investigation of genetic and epigenetic prognostic markers for prediction of clinical course of papillary thyroid cancer in different age groups". Project is carried out in accordance with the national program "Healthy aging". Head the project: Prof. PhD Birutė Žilaitienė. Project start at 01-10-2015 and will end at 2018-12-31. Budget - 199865 euros. Source of funding: Lithuanian Science Council.
The project is carried out under the program Healthy aging financed by Research Council of Lithuania. The aim of the current study is to identify specific miRNA as biomarkers for early diagnosis of papillary thyroid carcinoma (PTC) and to determine their diagnostic utility for predicting disease aggressiveness and clinical outcome. We will analyze 5 miRNAs (-146b, -221, -222, -181, -21) expression profiles between aggressive and nonaggressive PTC in large number of paraffin-embedded PTC tissue samples. Possible associations of miRNAs expression with BRAF V600E mutation within PTC tissue and clinicopathological features of PTC may help to improve tumor behavior prognostication. Identification of prognostic biomarkers would greatly improve patient management by facilitating the identification of patients with indolent PTC, who do not require aggressive treatment and to provide adequate intensive management for a subgroup of patients with aggressive disease. Investigation of circulating miRNAs (-146b, -221, -222, -181, -21) expression in patients with PTC, benign nodules and healthy controls may help to differentiate benign nodules from malignancies. Our identified molecular biomarkers will be employed to develop guidelines for early diagnosis of PTC and tumor behavior prognostication. The project should provide new knowledge about novel molecular biomarkers of PTC, which may improve diagnosis and treatment of disease, improving health outcomes and reducing the social and economic impact of disease.
Project “Genetic diabetes in Lithuania” (CH-3-ŠMM-01/09). Local supervisor - Prof. PhD Dalė Marčiulionytė. Project duration: November 2012 - April 2016. The project is funded by the support of Swiss Confederation and the Republic of Lithuania's budget. The project budget is 6.684.38.87€.
The program "Research and Development" is a constituent part of the Lithuanian-Swiss cooperation program. Project “Genetic diabetes in Lithuania” was developed in the frame of this program. based on the up-to-date scientific knowledge. The aims of this study:
1.To investigate different origins of diabetes in young population (
2. To perform genetic testing in subjects with non-autoimmune diabetes.
3. To compare metabolic control and diabetes complications prevalence between autoimmune and genetic diabetes patients.
Setting aside the origin of autoimmune diabetes in patients diagnosed with genetic diabetes, they will be permitted to switch from insulin to oral therapy products. This is the first and unique opportunity in Lithuania for patients to diagnose genetic diabetes free.
Project “Early Prevention of Diabetes Complications in Europe” was funded by SEVENTH FRAMEWORK. Project duration is 1st of January 2012 - 31st of July 2015. Local supervisor Prof. PhD Jilda Veličkienė. Project budget is 126.96.36.199€, Lithuanian part – 224.864.00 €.
PROGRAMME. General objective of project is to assess the long-term effects of different therapeutic regimens, both pharmacological and lifestyle interventions, for the early prevention of diabetic complications in people with intermediate hyperglycaemia (IFG or IGT) and screen-detected diabetes (SD-T2D). During the research 3000 45-74-year-aged patients from 12 countries will be examined.
Project “Active ageing with type 2 diabetes as model for development and implementation of innovative chronic care management in Europe (MANAGE-CARE)” was funded by SEVENTH FRAMEWORK PROGRAMME. Project duration: May 2013 - April 2016. Local supervisor Prof. PhD Jilda Veličkienė.
MANAGE-CARE focuses on prevention of costly complications and hospitalizations of patients with chronic diseases with diabetes as a model disease. Project budget was 1.154.069.00 €, Lithuanian part – 14.659.00 € .
Attendance in COST activities
Assoc. prof. habil. dr. Valentinas Matulevičius. MPNS COST Action TD1103. European Network for Hyperpolarization Physics and Methodology in NMR and MRI.
Prof. Rasa Verkauskienė, dr. Romualdas Tomas Preikša, prof. Birutė Žilaitienė, dr. Jonas Čeponis Cost Action BM1105. GnRH Deficiency: Elucidation of the neuroendocrine control of human reproduction.
Participation in the international non-budgetary programs:
1. DIAMOND (Diabetes Mondiale).
2. EURODIAB-TIGER (Europe and diabetes: type 1 genetic epidemiology resource).
3. LitDiane (The impact of clinical, genetic and environmental risk factors on the development of late complications in type 1 diabetes; The part of InterDiane consortium). Local supervisor Prof. PhD Rasa Verkauskienė.
The project is implemented at the Department of Endocrinology, Department of Ophthalmology, Department of Nephrology (Hospital of Lithuanian University of Health Sciences) and at the Institute of Endocrinology of the Medical Academy of Lithuanian University of Health Sciences.
The main aim of the study is try to explain why one third of all patients with type 1 diabetes develop late diabetic complications, that is, to identify clinical, genetic and environmental risk factors for the development and progression of diabetic micro- and macrovascular complications (nephropathy, retinopathy, central-peripheral-autonomic neuropathy, cardiovascular disease).